Collaborations & Alliances

Aevi Genomic Medicine, AstraZeneca Enter Into License Agreement

Plans to initiate Phase 2 trial for treatment of Adult Onset Still's Disease and other serious rare and orphan diseases

Aevi Genomic Medicine, Inc. has obtained the right to exercise an exclusive global license for MEDI2338, a Phase 2-ready fully human monoclonal antibody (mAb) that targets interleukin 18 (IL-18). The Company plans to initially develop MEDI2338 for adult onset Still’s disease (AOSD), a serious rare and orphan rheumatological disease with no currently approved biologic therapies in the US. Further development for several other rare autoinflammatory disorders that are driven by IL-18 will fol...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters